Article
Mutations in the epidermal growth factor receptor gene in non-small cell lung cancer: Impact on treatment beyond gefitinib and erlotinib.
Advances in therapy - 1 Feb 2011
Heigener David F, Reck Martin
Abstract excerpt
Epidermal growth factor receptor (EGFR)-activating mutations in non-small cell lung cancer (NSCLC) are molecular targets for treatment with gefitinib and erlotinib, often resulting in improved response and prolonged progression-free survival. Resistance to these drugs, which develops during treatment, is a problem of paramount importance. Several mechanisms of "acquired resistance" have been discovered and...
Topics
- Carcinoma, Non-Small-Cell Lung
- Clinical Trials as Topic
- Disease-Free Survival
- Drug Resistance, Neoplasm
- ErbB Receptors
- Erlotinib Hydrochloride
- Gefitinib
- Genes, erbB-1
- Humans
- Lung Neoplasms
- Molecular Targeted Therapy
- Mutation
- Protein Kinase Inhibitors
- Quinazolines